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Abstract
Background:  Theophylline has been used widely as a bronchodilator for the treatment of
bronchial asthma and has been suggested to modulate immune response. While the importance of
macrophages in asthma has been reappraised and emphasized, their significance has not been well
investigated. We conducted a genome-wide profiling of the gene expressions of macrophages in
response to theophylline.
Methods:  Microarray technology was used to profile the gene expression patterns of
macrophages modulated by theophylline. Northern blot and real-time quantitative RT-PCR were
also used to validate the microarray data, while Western blot and ELISA were used to measure the
levels of IL-13 and LTC4.
Results: We identified dozens of genes in macrophages that were dose-dependently down- or up-
regulated by theophylline. These included genes related to inflammation, cytokines, signaling
transduction, cell adhesion and motility, cell cycle regulators, and metabolism. We observed that
IL-13, a central mediator of airway inflammation, was dramatically suppressed by theophylline. Real-
time quantitative RT-PCR and ELISA analyses also confirmed these results, without respect to
PMA-treated THP-1 cells or isolated human alveolar macrophages. Theophylline, rolipram,
etazolate, db-cAMP and forskolin suppressed both IL-13 mRNA expression (~25%, 2.73%, 8.12%,
5.28%, and 18.41%, respectively) and protein secretion (<10% production) in macrophages. These
agents also effectively suppressed LTC4 expression.
Conclusion: Our results suggest that the suppression of IL-13 by theophylline may be through
cAMP mediation and may decrease LTC4 production. This study supports the role of theophylline
as a signal regulator of inflammation, and that down regulation of IL-13 by theophylline may have
beneficial effects in inflammatory airway diseases.
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Introduction
Asthma is a highly prevalent health problem worldwide
that may cause significant morbidity and mortality [1,2].
The mechanisms of airflow obstruction in asthma are var-
ious, including broncho-constriction with the contraction
of the airway's smooth muscle, increased secretion of
mucus, mucosal edema with vascular leakage, and the
infiltration of inflammatory cells [3]. The pathogenesis of
asthma and its susceptibility involve a complex interplay
of various genetic and environmental factors, which may
modulate airway inflammation and the remodeling proc-
esses that are not only present even in mild asthma but
also govern the appearance and severity of airway hyper-
responsiveness [4].
The inflammatory cells involved include the infiltration of
airway T cells, T helper cells, mast cells, basophils, eosi-
nophils, and macrophages [5]. Macrophages are the pre-
dominant immune effector in the alveolar spaces and
airway, and are believed to play a pivotal role in various
pulmonary inflammatory disorders [6,7]. Recently, their
importance in the pathogenesis of asthma has been reap-
praised and emphasized [8]. Although their role in asth-
matic inflammation is still incompletely understood, it is
clear that macrophages may participate in airway inflam-
mation though multiple mechanisms. Furthermore, mac-
rophages have been reported to release lukotriene B4
(LTB4), lukotriene C4 (LTC4), prostaglandin D2 (PGD2),
superoxide anion, and lysosomal enzymes in response to
immunoglobulin E (Ig E) [5,9,10]. They also produce
inflammatory mediators, such as platelet-activating fac-
tor, interleukin 1 beta (IL1β), IL-6, IL-8, and tumor necro-
sis factor- alpha (TNF-α) [11-14]. These mediators may
play important roles in producing broncho-constriction
or causing inflammatory changes.
Theophylline is a weak and non-selective inhibitor of
phosphodiesterase (PDE) in airway smooth muscle cells.
In high doses, theophylline may lead to an increase in
intracellular cAMP and cGMP, and mediate the relaxation
of airway smooth muscles and suppress airway inflamma-
tion [15]. In chronic obstructive pulmonary disease
(COPD) patients, theophylline can reduce the total
number and proportion of neutrophils, the production of
interleukin-8, and neutrophil chemotatic responses, fur-
ther suggesting its anti-inflammatory effects [15,16]. Sev-
eral studies have also demonstrated that theophylline has
a steroid-sparing effect [17,18]. Theophylline inhibits the
degranulation and release of mediators, including plate-
let-activating factor, LTC4, cationic proteins, and superox-
ide anion, from eosinophils, granulocytes, and alveolar
macrophages in vitro [19,20]. However, the effects of the-
ophylline on gene expressions in macrophages has not
been well studied.
In this study, we analyzed the expression profiles of
inflammation-related genes of macrophages in response
to theophylline, using a human cDNA microarray [21,22].
We also identified differentially expressed genes in macro-
phages after incubating with theophylline. Our study con-
firmed the diverse roles of theophylline as an immune
modulator, which may be helpful in improving its use in
the treatment of airway inflammatory disorders.
Methods
Cell lines, alveolar macrophage isolation, and theophylline 
treatment
Human monocyte cell line THP-1 (ATCC TIB 202; ATCC,
Manassas, VA) was grown with RPMI 1640 media
(GIBCO-BRL; Gaithersburg, MD) supplemented with 1.5
g/l Na2HCO3, 4.5 g/l glucose and 10% FBS (GIBCO-BRL)
and then incubated at 37°C with 20% O2 and 5% CO2·
3.2 × 10-7M PMA (SIGMA Chemical Co.; St. Louis, MO)
was applied to monocyte cultures. After incubating with
PMA for 24 hours, monocytes were differentiated into
macrophage-like phenotypes. Macrophages were washed
three times with RPMI medium containing 10% FBS and
incubated for another 24 hours to eliminate the effects of
PMA.
Alveolar macrophages were obtained by bronchoalveolar
lavage (BAL) during routine bronchoscopic examination
with written informed consent from three smoker patients
with chronic bronchitis. BAL was performed from the
right middle lobe or lingula using three to five successive
aliquots of 20 ml of 0.9% sterile NaCl. The BAL fluid was
centrifuged at 800 × g for 10 min at 4°C. After two wash-
ings, the cells were plated on plastic Petri dishes in serum-
free RPMI 1640 media and allowed to adhere for 2 h at
37°C. Non-adherent cells were removed by washings with
PBS. Adherent cells contained more than 95% alveolar
macrophages [23,24]. The 5 × 104 cells were plated on 24
well plates with complete RPMI medium. After incubating
for 24 hours, theophylline was added to the alveolar mac-
rophages. The study protocol was approved by the
National Taiwan University Hospital's Ethics Committee.
The designated concentration of theophylline (0, 2.5, 5,
10, and 20 µg/ml; SIGMA) was added to macrophages
(PMA-treated THP-1 cells). The drug treatments covered a
proper range of theophylline concentrations correspond-
ing to the clinical plasma therapeutic levels for asthma
patients [17,25]. After incubation for 24 hours, the cells
were harvested with RNAzol B and followed by microar-
ray experiments.
Human cDNA microarray analysis
Human EST clones with putative gene names were
obtained from the IMAGE consortium libraries through
its distributor (Research Genetics, Huntsville, AL). TheRespiratory Research 2005, 6:89 http://respiratory-research.com/content/6/1/89
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cDNA microarray with 9,600 PCR-amplified cDNA frag-
ments was prepared by an arraying machine. Five micro-
grams of mRNAs were labeled with Biotin-16-dUTP
during the reverse transcription as described in our previ-
ous report [22]. All of the experiments were individually
performed in triplicate. The microarray images were
scanned, digitized, and analyzed using a flat scanner
(PowerLook 3000, UMAX, Taipei, Taiwan) and GenePix
3.0 software (Axon, Union City, CA). The replicates were
used to calculate the mean and standard deviation of gene
expression and the coefficient of variation (CV) as the
measurement of reproducibility. The details of target
preparation, hybridization, color development, image
analysis, and spot quantification have been described pre-
viously [21,22]. (see online supplemental data for addi-
tional details on the microarray system) (see additional
file: 1).
Northern blotting and real-time quantitative RT-PCR
To confirm the results derived from the microarray, six dif-
ferentially expressed clones were randomly selected from
the cluster analysis and the entire inserts of the clones
were individually PCR-amplified to serve as probes for
Northern blotting. The amplified cDNA fragments were
labeled with digoxigenin-11-dUTP by random primed
labeling as our previous report [21]. To correct the quan-
tity of RNA loading, the signals were normalized with the
mRNA expression level of GAPDH in the same blot.
Due to the limitations of mRNA extraction from non-pro-
liferated macrophages and low expression levels of some
genes, we employed real-time quantitative RT-PCR (RTQ-
RT-PCR) with SYBR Green detection to confirm the results
derived from the microarray. There were eight differen-
tially expressed clones randomly selected from the cluster
analysis for RTQ-RT-PCR analyses. The TATA box binding
protein (TBP) was used as an internal control. The primers
were shown in Table 1 and detailed procedures have been
described previously [22]. All of the experiments were per-
formed in triplicate.
Western blotting analysis and ELISA
The details of nuclear extract preparation and Western
blot analysis have been described previously [26]. IL-13
was detected using a 1:500 dilution of mouse monoclonal
anti-IL-13 primary antibody, a 1:1000 dilution of HRP-
conjugated anti-mouse IgG secondary antibody (Santa
Cruz Biotech, Santa Cruz, CA), and the Western blotting
luminol reagent (Santa Cruz Biotech) as detection
reagent. α-tubulin, used as the control for gel loading, was
detected using mouse monoclonal anti-α-tubulin primary
antibody (Santa Cruz Biotech). In addition, the cultured
medium was collected and centrifuged to remove cellular
debris, and the supernatants were frozen at -80°C until
assayed by ELISA (R&D System Inc., Minneapolis, MN,
USA). IL-13 concentrations were determined by compari-
son to recombinant standards that run parallel with each
Table 1: Oligonucleotides for real-time quantitative RT-PCR
mRNA targets Oligonucleotides (5'→3') a Product size (bp)
IL-5 F180: ATAGCCAATGAGACTCTGAGGATTC 89
R268: AGTGTGCCTATTCCCTGAAAGAT
IL-13 F155: TGAGGAGCTGGTCAACATCA 76
R230: CAGGTTGATGCTCCATACCAT
IL-18 F211: GCTGAACCAGTAGAAGACAATTGC 94
R304: CCAGGTTTCATCATCTTCAGCTA
IL-13Rα1 F495: GGAATACCAGTCCCGACACTAACT 93
R587: GGCCTTCTCTAAAGATGTTTTCACA
IL-13Rα2 F44: GGCTATTTGAAGTCGCCATAACC 78
R121: AGATTTAAAACCTTGATATTGCCTCTCT
TNF-α F414: CTCGAACCCCGAGTGACAA 64
R477: AGCTGCCCCTCAGCTTGA
VEGF-a F1200: AACACACACTCGCGTTGCAA 69
R1268: CGGCTTGTCACATCTGCAAGT
VEGF-c F1193: AGATGCCTGGCTCAGGAAGA 74
R1266: ATGTCATGGAATCCATCTGTTGAGT
GM-CSF F119: GCCCTGGGAGCATGTGAA 78
R196: TTCATCTCAGCAGCAGTGTCTCTA
TBP F852: CACGAACCACGGCACTGATT 89
R940: TTTTCTTGCTGCCAGTCTGGAC
a F and R indicate forward and reverse primers, respectively. Numbers indicate the mRNA sequence position.Respiratory Research 2005, 6:89 http://respiratory-research.com/content/6/1/89
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batch of assays. Each sample was determined in duplicate.
The sensitivity of this ELISA was at < 32 pg/ml.
Statistical analysis
All of the experiments were performed in triplicate and
analyzed by ANOVA (Excel, Microsoft; Taipei, Taiwan). A
P value < 0.05 was considered statistically significant. In
an attempt to reduce variations arising from experimental
results of different microarrays, the intensity values of
spots from each microarray were re-scaled using a global-
scale method. Detailed procedures have been described
previously [21,22]. Where appropriate, the data are pre-
sented as the mean ± standard deviation. (see online sup-
plement for additional details on the microarray data
analysis) (see additional file: 1).
Results
Microarray analysis
Biotin-labeled probes deriving from mRNAs of macro-
phages (PMA-treated THP-1 cells) stimulated with differ-
ent concentrations of theophylline were hybridized to
microarrays with 9,600 putative genes to profile the gene
expression patterns. The CV was 5.26% and the Pearson
correlation coefficient of overall reproducibility for large-
scale analyses was 0.98. The results of microarray analyses
indicated that 2,724 out of 9,600 EST clones were identi-
fied, according to at least one dosage point, whose expres-
sion level is larger than the background (> 3,000 intensity
units).
Among these, 341 genes displayed more than a 2-fold
expression change across all five study-included dosages
in theophylline treatment. 75 genes were randomly
selected and sequenced retrospectively after differential
expressions were found, to assure that they indeed repre-
sented the true transcript. 45 genes were up-regulated and
30 genes were down-regulated by theophylline in macro-
phages (PMA-treated THP-1 cells). A full list of genes and
data related to treatment with theophylline were posted at
our Web site. http://w3.mc.ntu.edu.tw/department/gene
chip/supplement.htm. In addition, the gene lists of sup-
pressed and enhanced expression were shown in the
online data supplement as Tables 1 and 2 (see additional
file: 1).
These selected genes were grouped into eight categories by
their putative functions on the basis of literature reports
(Figure 1). The categories included: (1) cytoskeleton and
motility related genes (n = 11), such as caveolin-1 and
actin-related protein 3; (2) signal transduction related genes
(n = 21), such as testis-specific kinase 1 and IL-6 signal trans-
ducer, (3) transcription regulators (n = 9), such as trans-
forming growth β-Induced factor and Down syndrome critical
region protein 1; (4) transport regulators (n = 7), such as
CD36 and transcobalamin II; (5) cytokines (n = 4), such as
IL-13 and vascular endothelial growth factor (VEGF)-C; (6)
cell cycle regulators (n = 4), such as cyclin-dependent kinase
inhibitor 1C and  ecotropic viral integration site 2B; (7)
metabolism related genes (n = 35), such as platelet prote-
oglycan 1 and eukaryotic translation initiation factor 2, subu-
nit 3; and (8) miscellaneous genes (unknown) (n = 21),
such as KIAA0703 gene and KIAA0266. We found that
51% of affected genes were related to signal transduction
or metabolism. Genes with multiple roles were also
included in more than one category.
Northern blotting and RTQ-RT-PCR
To substantiate the results of the microarray studies,
Northern blot analysis and RTQ-RT-PCR were performed.
Six gene expressions that showed more than a 2-fold
change, including ETIF2S3, IRF7, IL6ST, TAFII55, PRG1
and TESK1, were randomly selected and evaluated. Figure
2A shows that the results of Northern blot analyses were
consistent with of the microarray studies. GAPDH  was
used as an internal control. The other eight genes selected
from microarray analysis were also confirmed by RTQ-RT-
PCR, including GMCSF, TNF-α, IL-13 Rα1, IL-13 Rα2, IL-
5,  IL-18,  VEGF-a, and VEGF-c  (Figure 2B). The IRF7,
TAFII55, PRG1, GMCSF, TNF-α, IL-13 Rα1, IL-5, and IL-18
genes were suppressed by theophylline, whereas ETIF2S3,
IL6ST,  TESK1,  IL-13 Rα2,  VEGF-a, and VEGF-c  were
stimulated.
Theophylline down-regulates IL-13 expression
Microarray analysis revealed that IL-13  expression was
dose-dependently suppressed by theophylline. Figure 3A
revealed a collection of cropped microarray images (3 × 3
spots) showing gene expression patterns of IL-13 in mac-
rophages (PMA-treated THP-1 cells) treated with theo-
phylline. Northern and Western blot analyses also
showed a similar suppression of IL-13 production (Figure
3B and 3C). The concentration of 10 µg/ml of theophyl-
line approximately corresponds to the clinical plasma
therapeutic level.
IL-13 mRNA expression in macrophages (PMA-treated
THP-1 cells) with different dosages of theophylline treat-
ment was measured by RTQ-RT-PCR, and results showed
a significant suppression compared with the control (α =
0.05, p = 0.0079) (Figure 4A). ELISA showed that IL-13
protein secretion was also reduced in a dose-dependent
manner (50.23%, 32.43%, 24.93%, and 5.33%,
respectively, of the level seen in the absence of theophyl-
line) (Figure 4B).
In this study, we also evaluated IL-13 expression in
human alveolar macrophages using ELISA. Results
showed that IL-13 protein secretion was reduced in alveo-
lar macrophages when treated by 10 µg/ml theophylline.
The amounts of IL-13 protein in those withoutRespiratory Research 2005, 6:89 http://respiratory-research.com/content/6/1/89
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theophilline treatment specimens BAL-A, BAL-B and BAL-
C are 224, 283 and 191 pg/ml, respectively. In contrast,
there are 86, 47, and 69 pg/ml of IL-13 in the respective
theophylline treatment specimens. In alveolar macro-
phages from smoker patients with chronic bronchitis, IL-
13 protein secretion was decreased in a dose-dependent
manner with theophylline (Figure 4C).
cAMP-dependent pathways in the down-regulation of IL-
13 expression
Since theophylline can effectively suppress the production
of IL-13 by macrophages, we then examined whether
other cAMP-related agents have the same effects. The des-
ignated dosages of two phosphodiesterase inhibitors type
IV (etazolate and rolipram) and two cAMP-elevating
Hierarchical clustering of the gene expression profile in macrophages with or without theophylline Figure 1
Hierarchical clustering of the gene expression profile in macrophages with or without theophylline. 75 differentially expressed 
genes dose-dependently down- or up-regulated by theophylline were identified and further grouped into 8 categories. Relative 
expression levels of these genes are color-coded.Respiratory Research 2005, 6:89 http://respiratory-research.com/content/6/1/89
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agents (forskolin and dibutyryl-cAMP) were added to
macrophages (PMA-treated THP-1 cells) separately for 24
hours. Dose-dependent suppression of IL-13 mRNA
expression were observed in all four drugs that could
increase intracellular cAMP levels (α = 0.05, p = 0.0009
compared to control) (Figure 5A). Similar results were
obtained with ELISA (α = 0.05, p = 0.0018 compared to
control) (Figure 5B).
Effects on LTC4 expression
The LTC4 is the downstream target of IL-13. Theophylline
and other four cAMP-related drugs (etazolate, rolipram,
forskolin, and db-cAMP) could dose-dependently
suppress LTC4 secretion by macrophages (Figure 6). As
shown in Figure 6A, LTC4 production in macrophages
(PMA-treated THP-1 cells) was significantly reduced to
78.34%, 34.63%, 23.32%, and 13.51% of the levels seen
Northern blot and real-time quantitative RT-PCR analyses of differentially expressed genes Figure 2
Northern blot and real-time quantitative RT-PCR analyses of differentially expressed genes. (A) Northern blot analysis of six 
randomly selected genes in macrophages. (B) Real-time quantitative RT-PCR analysis of eight cytokine genes. The relative 
amount of each cDNA level against to TBP cDNA was measured and defined by an arbitrary unit. (10 µg/ml of theophylline 
treatment approximately corresponds to the clinical plasma level.)Respiratory Research 2005, 6:89 http://respiratory-research.com/content/6/1/89
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in the absence of the drug, respectively, with different dos-
ages of theophylline. Similar results were observed in
macrophages (PMA-treated THP-1 cells) treated with
other cAMP-related drugs (Figure 6B).
Discussion
Macrophages are key inflammatory cells that have been
documented to play a critical role in various airway disor-
ders [8]. In this study, we analyzed the gene expression
profiles of macrophages in response to theophylline. A
panel of inflammation related genes was identified, as
well as genes associated with angiogenesis, cell adhesion,
cell motility, signal transduction, and cell proliferation
that are dose-dependently down- or up-regulated by theo-
phylline. Our results revealed that 45 genes were up-regu-
lated and 30 genes were down-regulated by theophylline
(supplemental Tables 1 and 2). We also found that theo-
phylline can down-regulate IL-13 expression in macro-
phages through cAMP mediation, which further leads to
decreased LTC4 production. Our results provide positive
evidence supporting the role of theophylline as a regula-
tor of inflammation.
In this report, interferon regulatory factor 7 (IRF-7) and
CD36 were both suppressed by theophylline in macro-
phages, especially in high dosages (Figures 1 and 2A, and
Supplemental Table 2). IRF-7 has been studied extensively
in viral infection [27] and can induce the gene expressions
of interferon and cytokine [28]. Interestingly, an over-
expression of IRF-7 can trigger monocyte differentiation
towards macrophages and induce cell cycle arrest, suggest-
ing a different function for IRF-7 in innate immunity [28].
Furthermore, CD36 is a multi-functional receptor that
may play important roles in monocyte/macrophage
biology, especially in atherogenic and inflammatory proc-
esses [29,30].
Airway inflammation in asthma is regulated by a complex
network of cytokines. We found that the expressions of
several cytokines were altered within the period of theo-
phylline stimulation (Figure 2B and supplemental Tables
1 and 2). Theophylline can suppress IL-5 and IL-13 pro-
duction by stimulating peripheral blood nuclear cells
(PBMC) [31]. Decreased expression of immuno-regula-
tory cytokines, including IL-12, IL-18, or interferon
gamma, can strengthen the inflammatory process and
IL-13 expression in macrophages was suppressed by theophylline in a dose-dependent manner Figure 3
IL-13 expression in macrophages was suppressed by theophylline in a dose-dependent manner. (A) Close-up view of microar-
ray digital image of IL-13 expression. (B) Northern blot analysis of IL-13 mRNA expression in macrophages. GAPDH was used 
as an internal control. (C) Western blot analysis revealed that IL-13 protein level in macrophages was decreased by theophyl-
line. α-tubulin was used as the loading control. 10 µg/ml of theophylline treatment approximately corresponds to the clinical 
plasma level.Respiratory Research 2005, 6:89 http://respiratory-research.com/content/6/1/89
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play regulatory roles in asthma by modifying Th2
lymphocyte responses [32]. Using a mouse model of aller-
gic inflammation, it has been shown that GMCSF signifi-
cantly contributes to the development of allergic airway
inflammation, and that dexamethasone can completely
inhibit GMCSF release [33]. Our findings reveal similar
results in the suppression of IL-5, IL-18, and GMCSF in
macrophages with theophylline (Figure 2B).
IL-13 is an immuno-regulatory cytokine secreted predom-
inantly by activated Th2 cells [34], and induces dramati-
cally different patterns of gene expression in primary
cultures of airway epithelial cells, airway smooth muscle
cells, and lung fibroblasts [35]. IL-13 expression is not
only in T cells and mast cells but also in both normal alve-
olar macrophages and those from subjects with pulmo-
nary fibrosis [36]. Some reports demonstrate that IL-13 is
overproduced in asthma and have implicated IL13 in
pathogenesis of inflammation and airway remodeling
responses [37-39]. Although the contribution of macro-
phage derived IL-13 to disease is still not clear, it has been
considered for therapy target because of its ability to stim-
ulate inflammatory and airway hyperreactivity responses.
In this study, there is strong evidence supporting that IL-
13 expression is down-regulated by theophylline in a
dose-dependent manner (Figures 3 and 4). We also fur-
ther confirmed the mRNA expression and protein secre-
tion of IL-13 with RTQ-RT-PCR and ELISA.
Effects of theophylline on IL-13 expression and protein secretion in macrophages Figure 4
Effects of theophylline on IL-13 expression and protein secretion in macrophages. (A) IL-13 mRNA level was measured by 
RTQ-RT-PCR, and significantly decreased after treating with theophylline (down to less than 45% compared with control. *α = 
0.05, p = 0.0079). (B) IL-13 protein secretion, by ELISA analysis, was also reduced in macrophages treated with theophylline. 
The trend was similar to that for the mRNA (down to less than 55% compared with control. *α = 0.05, p = 0.0075). (C) The 
IL-13 protein secretion in alveolar macrophages isolated from three patients (BAL-A, BAL-B, and BAL-C) with chronic bron-
chitis was also reduced when treated with 10 µg/ml theophylline (α = 0.05, p = 0.043; upper panel). The BAL-B specimens 
were treated with difference concentration of theophylline (0, 2.5, 5, 10, 20 µg/ml, respectively). IL-13 protein secretion was 
decreased in a dose-dependent manner with theophylline (lower panel). Arrow indicates the concentration of theophylline 
treatment corresponding to the clinical plasma levels (10 mg/L).Respiratory Research 2005, 6:89 http://respiratory-research.com/content/6/1/89
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In macrophages (PMA-treated THP-1 cells), IL-13Rα1
mRNA expression was inhibited by theophylline, whereas
IL-13Rα2 mRNA expression increased (Figure 2B). IL-13
modifies cell behavior by activating the signal transducer
and activator of transcription 6 (STAT-6). Consequently,
not only IL-13 concentration but also the density of IL-
13Rα1 expression may determine the role of IL-13 in the
regulation of inflammatory responses in affected tissues.
However, not all responses to IL-13 on monocytes and
macrophages are dependent on signaling via IL-13Rα1
and significant STAT6 activation [40]. Leukotrienes, the
products of lipoxygenases, are thought to be important
mediators of IL-13-induced asthma phenotype [41]. LTC4
stimulates eotaxin production by IL-13 treated fibroblasts,
thereby indirectly inducing eosinophil sequestration [42].
Recently, some studies demonstrated that the regulation
of cAMP level by inhibiting PDE activity appears to be
involved in the regulation IL-13 release [43,44]. The type
IV PDE inhibitors have the potential to exert an anti-
inflammatory effect by inhibiting IL-13 production in
lymphocyte and peripheral blood mononuclear cells
[43,44].
In this study, we also investigated the influence of cAMP
pathway on IL-13 and LTC4 expression in macrophage.
We found that etazolate and rolipram, which are PDE type
IV inhibitors, can significantly inhibit IL-13 and LTC4
Suppression of IL-13 expression in macrophages by PDE type  IV inhibitors and cAMP-elevating agents Figure 5
Suppression of IL-13 expression in macrophages by PDE type 
IV inhibitors and cAMP-elevating agents. Two PDE type IV 
inhibitors, etazolate and rolipram, and two cAMP-elevating 
agents, forskolin and db-cAMP (dibutyryl-cAMP), were added 
to macrophage separately for 24 hours. The cells were har-
vested to extract RNA for RTQ-RT-PCR, and the cultured 
medium were used to carry out ELISA. (A) RTQ-RT-PCR 
analysis showed a decrease of IL-13 mRNA in a dose-
dependent manner after treating with four drugs (α = 0.05, p 
= 0.0009). (B) The results of ELISA also revealed that IL-13 
protein secretion was reduced after treatment with four 
drugs (α = 0.05, p = 0.0018).
LTC4 secretion by macrophages was suppressed by theo- phylline and cAMP signaling regulators in a dose-dependent  pattern Figure 6
LTC4 secretion by macrophages was suppressed by theo-
phylline and cAMP signaling regulators in a dose-dependent 
pattern. The cultured medium of macrophages treated with 
tested drugs was collected to perform ELISA. (A) LTC4 pro-
tein secretion was reduced by theophylline stimulation. (B) 
Etazolate, rolipram, forskolin, and db-cAMP (dibutyryl-cAMP) 
also suppressed LTC4 protein secretion. Arrow indicates the 
concentration of theophylline treatment corresponding to 
the clinical plasma levels (10 mg/L).Respiratory Research 2005, 6:89 http://respiratory-research.com/content/6/1/89
Page 10 of 12
(page number not for citation purposes)
production in mRNA and protein level. Similar
suppressions are shown in treatment with PKA activator
(forskolin and dibutyryl-cAMP). The results indicate that
the inhibition of IL-13 and LTC4 might through cAMP
and PKA mediation in macrophage. However, the role of
PKA in anti-inflammatory effects through cAMP media-
tion is less established. Although most of the cAMP
exerted its downstream effects though the PKA dependent
pathway, some actions of cAMP have been reported to be
independent of PKA, including the activation of small
GTPase Rap1 [45].
In addition, several lines of evidence support that cAMP
may act at transcription, post-transcription, or translation
levels. For example, cAMP elevating agents can repress NF-
kappaB dependent transcription by a variety of mecha-
nism [46], and NF-kappaB is also known to be involved in
the induction of TNF-alpha, IL-3, and IL-13 in human
mast cells [47]. Although the mechanism involved in the
regulation of cAMP and IL-13 is still unclear, this study
suggests that a possible pathway of the suppressive effects
of theophylline on IL-13 expression may be through a
cAMP mediated regulation.
As shown in Figure 7, we summarized a model for the pos-
sible gene regulation in macrophages (PMA-treated THP-
1 cells) stimulated by theophylline. Our results suggested
that the suppression of IL-13 by theophylline may be
through the cAMP pathway and further inhibits the
expression of LTC4 and LTD4.
Conclusion
These data may facilitate the understanding of the diverse
anti-inflammatory effects of theophylline, as well as the
potential contributing role of macrophages in the
pathogenesis of asthma. The importance of theophylline
as a signal regulator of inflammation should be re-empha-
sized. Our results suggest that theophylline could down-
regulate IL-13 expression in macrophages through cAMP
mediation, and further lead to a decrease in LTC4
production, which may have beneficial effects on the ther-
apeutic use of theophylline in pulmonary inflammatory
diseases.
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